Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intelligent Bio Solutions (INBS) Common Equity (2019 - 2025)

Intelligent Bio Solutions has reported Common Equity over the past 6 years, most recently at $8.2 million for Q2 2024.

  • For Q2 2024, Common Equity rose 121.95% year-over-year to $8.2 million; the TTM value through Jun 2024 reached $8.2 million, up 121.95%, while the annual FY2024 figure was $8.2 million, 121.95% up from the prior year.
  • Common Equity for Q2 2024 was $8.2 million at Intelligent Bio Solutions, down from $11.0 million in the prior quarter.
  • Over five years, Common Equity peaked at $18.8 million in Q4 2020 and troughed at -$5.9 million in Q1 2020.
  • A 5-year average of $6.8 million and a median of $7.4 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: soared 543.02% in 2021 and later crashed 76.2% in 2023.
  • Year by year, Common Equity stood at $18.8 million in 2020, then crashed by 46.52% to $10.0 million in 2021, then grew by 2.17% to $10.3 million in 2022, then plummeted by 69.27% to $3.2 million in 2023, then surged by 159.44% to $8.2 million in 2024.
  • Business Quant data shows Common Equity for INBS at $8.2 million in Q2 2024, $11.0 million in Q1 2024, and $3.2 million in Q4 2023.